| 영문 | solid tumor | 한글 | 고형종양 |
|---|---|---|---|
| 설명 | 세포로 꽉 찬 종양을 말함. 백혈병 등의 혈액암과 같이 형태를 취하지 않고 액체인 상태의 암과 대조되는 용어로서 단단한 덩어리로 구성된 악성종양이다. 대부분의 종양이 이에 해당한다. 특히 표피조직에서 기원한 종양을 말한다. |
||
| 영문 | ulcerating tumor | 한글 | 궤양성 종양 |
|---|---|---|---|
| 설명 | 종양의 표면에 궤양이 발생하는 것. 대개, 매우 빨리 자라는 종양에서 혈류 공급이 종양세포의 자라는 속도를 감당하지 못해 종양중심부 조직이 괴사에 빠져 궤양을 형성하는 경우가 많다. 육안으로 보면 빨갛고, 열이나며, 지저분해 보인다. |
||
| 영문 | brain tumor | 한글 | 뇌종양 |
|---|---|---|---|
| 설명 | 뇌종양이란 뇌와 뇌조직에서 생긴 종양을 지칭하는 말이다. 그러나 대개 넓은 의미로 사용할 경우에는 머리뼈속의 공간인 두개강속에 생기는 모든 종양을 이르는 말로 사용된다. 뇌종양은 한정된 공간인 두개강에서 발생하므로 종양이 그다지 크지 않아도 정상적인 조직을 압박하게 되고, 두개강내의 압력을 높인다. 이런 특징에 의해서 뇌종양의 증상은 다른 종양과 달리, 종양 그 자체의 증상보다도 두개내압상승과 정상조직의 압박에 의한 증상이 많다. 두개내압(뇌압)의 상승에 의한 증상으로는 두통, 구토등이 있으며, 지속적인 뇌압상승에 의해서 유두부종(papilledema)이 관찰되기도 한다. 그리고 정상적인 뇌조직의 압박과 종양이 생긴 부위의 기능의 결합에 뇌의 그 부분에 해당하는 기능의 상실을 보게된다. |
||
| 영문 | epithelial tumor | 한글 | 상피성종양 |
|---|---|---|---|
| 설명 | 정상 사람의 조직은 체표면을 덮는 역할을 하는 조직과, 주로 발생기의 중배엽에서 분화한 간엽조직에서 유래하는 결합조직, 뼈, 연골, 지방, 근육, 혈관 등의 조직의 두 계통으로 나눌 수 있다. 전자를 상피성 조직, 후자를 비상피성 조직이라 하며 그 각각을 구성하는 세포를 상피성 세포, 비상피세포라 총칭한다. 상피성 세포에서 기원하는 종양이 상피성 종양이며, 근처의 조직으로 침투나 혈류, 림프의 조직을 타고 원거리의 장기로 이동하지 않는 양성종양에는 선종, 유두종 등이 있고 양성과 반대로 근처의 조직으로 침투, 원격장기로 전이하는 악성종양을 모두 통칭하여 암종(carcinoma)이라고 한다. |
||
| 영문 | medullary tumor | 한글 | 수질성 종양 |
|---|---|---|---|
| 설명 | 암의 병리학적인 분류중 하나. 여러 기관의 암에서 나타나는데 주로 갑상샘암이나 유방암에서 보인다. |
||
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
|---|---|
| ITP | idiopathic thrombocytopenic purpura; immune thrombocytopenia; immunogenic thrombocytopenic purpura; ... |
| GCT | general care and treatment; germ-cell tumor; giant cell thyroiditis; giant cell tumor |
| AFP | Alpha(α) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| ICA | Islet Cell-Cytoplasmic Antibodies |
|---|---|
| ICA | Islet cell |
| ICA | Islet cell antibodies |
| ICAs | Islet cell antibodies |
| ICA | Islet cell antibody |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| adenoma, islet cell | A benign tumour of the islets of langerhans that may occur anywhere throughout the pancreas. Such tumours may result in hyperinsulinism or zollinger-ellison syndrome. (12 Dec 1998) |
| carcinoma, islet cell | A carcinoma of the islets of langerhans. (12 Dec 1998) |
| pancreatic isleT-cell tumours | <radiology> Insulinoma (beta-cell), usually solitary, 85% benign, gastrinoma, small, slow-growing, multiple, 60% malignant, Zollinger-Ellison syndrome: mult. Intractable ulcers, VIPoma, vasoactive intestinal peptide (VIP), WDHA syndrome: watery diarrhoea, hypokalaemia, achlorhydria, Verner-Morrison syndrome, glucagonoma, hyperglycaemia, migratory necrolytic erythema APUDomas, associated with MEN-1 (12 Dec 1998) |
| islet cell | <pathology> Cells of the Islets of Langerhans within the pancreas. See: A cells, B-cells, D cells. (18 Nov 1997) |
| islet cell adenoma | <tumour> A benign neoplasm of the pancreas composed of tissue similar in structure to that of the islets of Langerhans; it may contain functioning beta cells, and may cause hypoglycaemia. See: insulinoma. Synonym: nesidioblastoma. (05 Mar 2000) |
| islet cell antibodies | In first-degree relatives of probands with insulin-dependent diabetes mellitus the presence of high titre ICA of the IgG cytoplasmic variety (IgG -ICA) and ICA of the complement-fixing subgroup (CF-ICA) confer a relative risk of 75 for development of insulin-dependent diabetes mellitus. The presence of ICA combined with a decrease in the first-phase of insulin secretion ( less than 25 micro U/mL) is predictive with a 95% likelihood of the development of insulin-dependent diabetes mellitus within 12 months. Reproducible results among laboratories are possible with careful attention to selection of the human pancreas as substrate as well as to the use of dilutions to generate standard curves and to the conversion of results to units. The prozone phenomena described elsewhere are not common in our experience. Fifty percent of relatives with a single positive ICA test will develop insulin-dependent diabetes mellitus within 10 years, and 60-80% of relatives with both ICA and insulin autoantibodies (IAA) will develop insulin-dependent diabetes mellitus within 10 years. The predictive value for health of negative results for ICA and IAA is almost 99%. Strong, persistently positive ICA (i.e., 40 JDF U or greater), especially if accompanied by markedly decreased insulin secretion, are the best predictors of subsequent development of insulin-dependent diabetes mellitus. The 64 kD beta-cell autoantigen long thought to be an important target for ICA is not yet available from expression cloning despite efforts by several groups.13 ICA positivity correlates with rapid loss of C-peptide secretory capacity in newly diagnosed ICA-positive insulin-dependent diabetes mellitus. The predictive values of ICA for development of insulin-dependent diabetes mellitus within 10 years in first-degree relatives of patients with insulin-dependent diabetes mellitus increase from 40% at low levels of ICA to 100% at high levels, whereas the sensitivity is 88% at low levels and 31% at high levels. In general, the risk of insulin-dependent diabetes mellitus in relatives of probands increases with titre of ICA, is greater in multiplex families, and is increased in those less than 10 years of age with positive ICA. Although the prevalence of ICA in Japanese with autoimmune thyroid disease resembles that in Caucasians, the incidence of insulin-dependent diabetes mellitus in the Japanese population is only 1/30 - 1/50 that in Caucasians. Prediabetics positive for ICA and IAA have increased suppressor-inducer (CD45R) and decreased helper-inducer (CDw29) peripheral blood lymphocytes. In two randomised, prospective, placebo-controlled studies of recent-onset insulin-dependent diabetes mellitus, cyclosporine immunosuppression increased the rate of non-insulin-requiring remissions as well as beta-cell function during drug treatment. Although 12 months of cyclosporine therapy decreases titres of ICA and insulin antibodies (IA) and increases glucagon-stimulated levels of serum C-peptide, the determination of ICA and IA and HLA-DR type are of no predictive value in selecting recent- onset insulin-dependent diabetes mellitus. Patients for cyclosporine immunointervention. Genetic control of autoimmunity in insulin-dependent diabetes mellitus is reviewed. EIA for autoantibodies to a 64 kD islet-cell protein is promising for prediction of insulin-dependent diabetes mellitus, but sensitivity and specificity are still suboptimal. See also: insulin antibodies. (05 Mar 2000) |
| islet cell antigen-related protein-tyrosine phosphatase | <enzyme> Receptor-like autoantigen found in insulin-dependent diabetes; genbank l76258 Registry number: EC 3.1.3.- Synonym: iar ptp (26 Jun 1999) |
| islet-cell-stimulating antibodies | <immunology> Autoantibodies to a putative beta-cell receptor; stimulate the release of insulin both in rodents and man; may be analogous to the thyroid stimulating antibodies that cause grave's hyperthyroidism Synonym: icsta (05 Dec 1998) |
| blood islet | An aggregation of splanchnic mesodermal cells on the embryonic yolk sac, with the potentiality of forming vascular endothelium and primitive blood cells. Synonym: blood islet. (05 Mar 2000) |
| islet | A small island. (05 Mar 2000) |
| islet amyloid peptide | <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide. (15 Oct 1997) |
| islet neogenesis-associated protein | <chemical> Constituent of ilotropin; stimulates proliferation of pancreatic ductal cells in vitro; from hamsters and humans; amino acid sequence given in first source Synonym: ingap protein, ingap gene product (05 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|